Secukinumab is a fully human monoclonal antibody that selectively neutralizes interleukin-17A (IL-17A). It was the first IL-17A antagonist approved by the FDA for moderate-to-severe plaque psoriasis. This reagent is widely used in immunology and dermatology research, including in vitro cytokine blockade studies and in vivo models of autoimmune inflammation.
Concentration:
8.2 mg/mL
Molecular Weight:
147.93 kDa
Purity:
99.10% (May vary between batches)
CAS Number:
[1229022-83-6]
Target:
Interleukin,IL Receptor
* VAT and and shipping costs not included. Errors and price changes excepted
